Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen D Shafran

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|December 27, 2007
Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDSRichard G Lalonde, Guy Boivin, Jean Deschênes, et al.
Antiviral Therapy|November 2, 2018
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C)Fred Poordad, Mitchell L Shiffman, Wayne Ghesquiere, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2005
Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccineDavid I Bernstein, Fred Y Aoki, Stephen K Tyring, et al.
The Journal of Infectious Diseases|July 9, 2018
Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 GenotypesSergio M Borgia, Charlotte Hedskog, Bandita Parhy, et al.
Journal of Viral Hepatitis|June 20, 2019
Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infectionTarik Asselah, Stephen D Shafran, Stefan Bourgeois, et al.
Hepatology (Baltimore, Md.)|March 19, 2013
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trialMark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, et al.
Open Forum Infectious Diseases|April 6, 2019
Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV ClassificationCharlotte Hedskog, Bandita Parhy, Silvia Chang, et al.
Annals of Internal Medicine|November 6, 2002
Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapyStephen D Shafran, Laura D Mashinter, Peter Phillips, et al.
Journal of Hepatology|December 10, 2017
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studiesChristophe Hezode, Nancy Reau, Evguenia S Svarovskaia, et al.
HIV Clinical Trials|October 25, 2007
Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimenMona R Loutfy, Nabil Ackad, Tony Antoniou, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|December 27, 2007
Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDSRichard G Lalonde, Guy Boivin, Jean Deschênes, et al.
Antiviral Therapy|November 2, 2018
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C)Fred Poordad, Mitchell L Shiffman, Wayne Ghesquiere, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2005
Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccineDavid I Bernstein, Fred Y Aoki, Stephen K Tyring, et al.
The Journal of Infectious Diseases|July 9, 2018
Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 GenotypesSergio M Borgia, Charlotte Hedskog, Bandita Parhy, et al.
Journal of Viral Hepatitis|June 20, 2019
Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infectionTarik Asselah, Stephen D Shafran, Stefan Bourgeois, et al.
Hepatology (Baltimore, Md.)|March 19, 2013
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trialMark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, et al.
Open Forum Infectious Diseases|April 6, 2019
Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV ClassificationCharlotte Hedskog, Bandita Parhy, Silvia Chang, et al.
Annals of Internal Medicine|November 6, 2002
Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapyStephen D Shafran, Laura D Mashinter, Peter Phillips, et al.
Journal of Hepatology|December 10, 2017
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studiesChristophe Hezode, Nancy Reau, Evguenia S Svarovskaia, et al.
HIV Clinical Trials|October 25, 2007
Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimenMona R Loutfy, Nabil Ackad, Tony Antoniou, et al.
Pageof 4